Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Strong antitumor activity of bevacizumab and aflibercept in Neuroendocrine Carcinomas: In-depth preclinical study.

Rodriguez-Remirez M, Del Puerto-Nevado L, Fernández Aceñero MJ, Ebrahimi-Nik H, Cruz-Ramos M, Garcia-Garcia L, Solanes S, Baños N, Molina-Roldan E, Garcia-Foncillas J, Cebrián A.

Neuroendocrinology. 2019 Apr 29. doi: 10.1159/000500591. [Epub ahead of print]

PMID:
31030198
2.

UNR/CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition.

Martinez-Useros J, Garcia-Carbonero N, Li W, Fernandez-Aceñero MJ, Cristobal I, Rincon R, Rodriguez-Remirez M, Borrero-Palacios A, Garcia-Foncillas J.

J Clin Med. 2019 Apr 25;8(4). pii: E560. doi: 10.3390/jcm8040560.

3.

Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer.

Cruz-Ramos M, Del Puerto-Nevado L, Zheng B, López-Bajo R, Cebrian A, Rodríguez-Remirez M, García-García L, Solanes-Casado S, García-Foncillas J.

J Geriatr Oncol. 2018 Oct 13. pii: S1879-4068(18)30256-X. doi: 10.1016/j.jgo.2018.10.002. [Epub ahead of print]

PMID:
30327283
4.

UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.

Martinez-Useros J, Georgiev-Hristov T, Fernández-Aceñero MJ, Borrero-Palacios A, Indacochea A, Guerrero S, Li W, Cebrián A, Gómez Del Pulgar T, Puime-Otin A, Del Puerto-Nevado L, Rodríguez-Remírez M, Pérez N, Celdrán A, Gebauer F, Garcia-Foncillas J.

PLoS One. 2017 Aug 1;12(8):e0182044. doi: 10.1371/journal.pone.0182044. eCollection 2017.

5.

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.

Cebrián A, Gómez Del Pulgar T, Méndez-Vidal MJ, Gonzálvez ML, Lainez N, Castellano D, García-Carbonero I, Esteban E, Sáez MI, Villatoro R, Suárez C, Carrato A, Munárriz-Ferrándiz J, Basterrechea L, García-Alonso M, González-Larriba JL, Perez-Valderrama B, Cruz-Jurado J, González Del Alba A, Moreno F, Reynés G, Rodríguez-Remírez M, Boni V, Mahillo-Fernández I, Martin Y, Viqueira A, García-Foncillas J.

Sci Rep. 2017 Jan 24;7:41371. doi: 10.1038/srep41371.

6.

Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy.

Cebrián A, Gómez Del Pulgar T, Fernández-Aceñero MJ, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, Marín-Arango JP, Caramés C, Vega-Bravo R, Rodríguez-Remírez M, Manzarbeitia F, García-Foncillas J.

Pathol Res Pract. 2016 Dec;212(12):1133-1137. doi: 10.1016/j.prp.2016.09.012. Epub 2016 Sep 22.

PMID:
27712975
7.

Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study.

Del Puerto-Nevado L, Marin-Arango JP, Fernandez-Aceñero MJ, Arroyo-Manzano D, Martinez-Useros J, Borrero-Palacios A, Rodriguez-Remirez M, Cebrian A, Gomez Del Pulgar T, Cruz-Ramos M, Carames C, Lopez-Botet B, Garcia-Foncillas J.

BMC Cancer. 2016 Jul 25;16:519. doi: 10.1186/s12885-016-2574-9.

8.

Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer.

Aguilera O, Muñoz-Sagastibelza M, Torrejón B, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, Rodriguez-Remirez M, Zazo S, García E, Fraga M, Rojo F, García-Foncillas J.

Oncotarget. 2016 Jul 26;7(30):47954-47965. doi: 10.18632/oncotarget.10087.

9.

Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer.

Gómez Del Pulgar T, Cebrián A, Fernández-Aceñero MJ, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, Marín-Arango JP, Caramés C, Vega-Bravo R, Rodríguez-Remírez M, Cruz-Ramos M, Manzarbeitia F, García-Foncillas J.

J Cell Mol Med. 2016 Sep;20(9):1729-36. doi: 10.1111/jcmm.12879. Epub 2016 May 12.

10.

DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.

Martinez-Useros J, Rodriguez-Remirez M, Borrero-Palacios A, Moreno I, Cebrian A, Gomez del Pulgar T, del Puerto-Nevado L, Vega-Bravo R, Puime-Otin A, Perez N, Zazo S, Senin C, Fernandez-Aceñero MJ, Soengas MS, Rojo F, Garcia-Foncillas J.

BMC Cancer. 2014 Dec 16;14:965. doi: 10.1186/1471-2407-14-965.

Supplemental Content

Loading ...
Support Center